Floatz logo

cd7.car/28zeta car t cells

CD7+ Lymphoma

Zhengzhou UniversityCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the CD7+ Lymphoma cohort.

Asset / SponsorPhaseRating
Anti-Cd7 Car-T
Zhejiang University
Phase 1CC

Same molecule, other indications

cd7.car/28zeta car t cells is also rated in:

T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
T-lymphoblastic lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
CD7 PositiveDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →